
1. open forum infect dis. 2014 dec 13;1(3):ofu110. doi: 10.1093/ofid/ofu110.
ecollection 2014 dec.

subgroup differences response 8 weeks ledipasvir/sofosbuvir chronic 
hepatitis c.

o'brien tr(1), lang kuhs ka(1), pfeiffer rm(2).

author information: 
(1)infections immunoepidemiology branch .
(2)biostatistics branch, division cancer epidemiology genetics , national 
cancer institute , bethesda, maryland.

treatment hepatitis c virus (hcv) infection ledipasvir/sofosbuvir
promises tremendous benefits, high cost may impede implementation this
regimen. subgroups excellent response 8 weeks treatment might respond 
to shorter course. ion-3, 423 previously untreated hcv genotype 1-infected
patients without cirrhosis outcome data receiving ledipasvir/sofosbuvir
for 8 weeks. reanalyzing published ion-3 data, found sustained
virologic response (svr) rates varied significantly gender (p = .002) and
rs12979860 genotype (p trend = .03), exceeding 98% women rs12979860-cc
individuals. high svr rates subgroups suggest these
factors might considered selecting patients receive 8 weeks of
ledipasvir/sofosbuvir support shorter trials regimen selected
patients.

doi: 10.1093/ofid/ofu110 
pmcid: pmc4324232
pmid: 25734178 

